IDH2 and neoplasm: In addition, the patient had a tumor-specific mutation of the PIK3CA gene at exon 20, a missense mutation with mutation type c.3140A>G (p.H1047R), and mutation abundance of 25.00% as well as IDH2 gene mutation P.R172T at exon 4, missense mutation with mutation type c.515G>C (p.R172T), and mutation abundance of 21.91%; this is a non-embryonic mutation that is not hereditary and is consistent with the existing findings.